Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of LY3537021 with Liraglutide in Healthy Participants
NCT05444569Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3537021 in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started Aug 2022; status: completed.
02
Drugs
LY3537021
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05444569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05444569.